NCT01915524View on ClinicalTrials.gov

Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Non-Small Cell Lung Carcinoma
Interventions
BIOLOGICAL

CV9202

Intradermal injection of CV9202

RADIATION

local radiation

Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week

Trial Locations (13)

4301

University Hospital Basel, Clinic for Oncology, Basel

6020

Innsbruck Medical University, Department of Internal Medicine V (Hematology and Oncology), Innsbruck

7000

Kantonsspital Graubünden, Chur

8401

Kantonspital Winterthur, Oncology, Winterthur

9007

Kantonspital St. Gallen, Sankt Gallen

14165

HELIOS Klinikum Emil von Behring GmbH, Berlin

26121

Pius-Hospital Oldenburg, Oldenburg

44791

Augusta-Kranken-Anstalt gGmbH, Bochum

51109

Kliniken der Stadt Köln gGmbH, Cologne

55131

University Medical Center Mainz, III. Medical Clinic and Policlinic, Mainz

60590

University Hospital Frankfurt, Department of Medicine II: Hematology/Oncology, Frankfurt

69127

Thoraxklinik-Heidelberg gGmbH, Heidelberg

73730

Klinikum Esslingen GmbH, Esslingen am Neckar

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
lead

CureVac

INDUSTRY

NCT01915524 - Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter